Premium
Absence of Clinically Relevant Pharmacokinetic Interaction Between Ribavirin and Tenofovir in Healthy Subjects
Author(s) -
Ramanathan Srinivasan,
Cheng Andrew,
Mittan Angelique,
Ebrahimi Ramin,
Kearney Brian P.
Publication year - 2006
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006287704
Subject(s) - pharmacokinetics , ribavirin , tenofovir , medicine , pharmacology , pharmacokinetic interaction , drug interaction , virology , human immunodeficiency virus (hiv) , virus , hepatitis c virus
This was a 36‐day, open‐label, fixed‐sequence, multiple‐dose drug interaction study in 23 healthy subjects to evaluate the effects of multiple doses of tenofovir disoproxil fumarate on the single‐dose pharmacokinetics of ribavirin. Subjects received a 600‐mg once‐daily oral dose of ribavirin on days 1 and 22 and 300‐mg once‐daily oral doses of tenofovir disoproxil fumarate on days 17 through 24. Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25. Pharmacokinetics of ribavirin was not altered by its coadministration with tenofovir disoproxil fumarate as the point estimates (day 22 [test treatment]/day 1 [reference treatment]), and the 90% confidence interval for maximum observed concentration (0.95; 88.7–101) and area under the plasma concentration‐time curve up to time of last measurable concentration (1.12; 106–117) were within the equivalence bounds of 80% to 125%. Tenofovir pharmacokinetics after ribavirin coadministration was similar to that observed in previous studies. These results indicate that coadministration of tenofovir disoproxil fumarate and ribavirin does not result in substantial changes to their individual pharmacokinetic profiles.